Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

L.A. McKeown

December 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2017

Shelley Wood

November 29, 2017

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

News Daily News

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Michael O'Riordan

October 26, 2017

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

News Daily News

Ischemic Heart Disease the Leading Cause of Death Globally

Michael O'Riordan

September 19, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Todd Neale

August 27, 2017

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

Leah Lawrence

July 24, 2017

News Daily News

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Michael O'Riordan

July 03, 2017

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

L.A. McKeown

May 23, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

Todd Neale

May 05, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

Advertisement

Secondary Prevention Improves Survival After STEMI Discharge but Is Widely Underprescribed

TCTMD’s Top 10 Most Popular Stories for November 2017

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Ischemic Heart Disease the Leading Cause of Death Globally

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Long-term Ticagrelor Post-MI of ‘Intermediate Value’: Cost-Effectiveness Study

More Vascular Complications, Higher 30-Day Mortality With PCI Prior to TAVR: Meta-Analysis

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content